Monte Rosa Therapeutics, Inc. announced its second development candidate, MRT-6160, a novel, potent, and selective molecular glue degrader (MGD) of VAV1. The Company plans to file an Investigational New Drug (IND) application for MRT-6160 in the first half of 2024 and to develop the molecule as a potential treatment for autoimmune diseases.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.33 USD | -2.20% | -8.89% | -5.66% |
Mar. 14 | Monte Rosa Therapeutics Q4 Net Loss Narrows; Shares Decline | MT |
Mar. 14 | Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.66% | 268M | |
+1.51% | 42.75B | |
+49.05% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- GLUE Stock
- News Monte Rosa Therapeutics, Inc.
- Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, A Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases